Related references
Note: Only part of the references are listed.Competitive inhibition of histone deacetylase activity by trichostatin A and butyrate
Anoushe Sekhavat et al.
BIOCHEMISTRY AND CELL BIOLOGY (2007)
A functional genetic screen identifies retinoic acid signaling as a target of histone deacetylase inhibitors
Mirjam T. Epping et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Solid lipid nanoparticles incorporating melatonin as new model for sustained oral and transdermal delivery systems
Lorenzo Priano et al.
JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY (2007)
Phenylbutyrate sensitizes human glioblastoma cells lacking wild-type p53 function to ionizing radiation
Carlos A. Lopez et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2007)
Solid lipid nanoparticles for targeted brain drug delivery
Paolo Blasi et al.
ADVANCED DRUG DELIVERY REVIEWS (2007)
Anti-inflammatory properties of the short-chain fatty acids acetate and propionate: A study with relevance to inflammatory bowel disease
Sofia Tedelind et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2007)
Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma
R. K. Lindemann et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
In vivo efficacy of a novel histone deacetylase inhibitor in combination with radiatio or the treatment of gliomas
Michal Entin-Meer et al.
NEURO-ONCOLOGY (2007)
Solid lipid nanoparticles: could they help to improve the efficacy of pharmacologic treatments for brain tumors?
Andrea Brioschi et al.
NEUROLOGICAL RESEARCH (2007)
Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy
E. Mercuri et al.
NEUROLOGY (2007)
Histone deacetylase inhibitor and demethylating agent chromatin compaction and the radiation response by cancer cells
Gil Bar-Sela et al.
CANCER JOURNAL (2007)
Histone deacetylases: Focus on the nervous system
B. E. Morrison et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2007)
Histoine deacetylase inhibitors in cancer therapy: Latest developments, trends and medicinal chemistry perspective
Konstantin V. Balakin et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2007)
Histone deacetylase inhibitors: Biology and mechanism of action
Janice M. Mehnert et al.
CANCER JOURNAL (2007)
Molecular changes in brain tumors: prognostic and therapeutic impact
Marc Sanson et al.
CURRENT OPINION IN ONCOLOGY (2006)
Recent advances in immunotherapy for human glioma
Antoine E. Carpentier et al.
CURRENT OPINION IN ONCOLOGY (2006)
Mitochondrial-dependent Ca2+ handling in Huntington's disease striatal cells:: Effect of histone deacetylase inhibitors
Jorge M. A. Oliveira et al.
JOURNAL OF NEUROSCIENCE (2006)
Prognostic stratification of patients with anaplastic gliomas according to genetic profile
Caroline Dehais et al.
CANCER (2006)
The selectivty and anti-metastatic activity of oral bioavailable butyric acid prodrugs
A Rephaeli et al.
INVESTIGATIONAL NEW DRUGS (2006)
Intracellular accumulation and cytotoxicity of doxorubicin with different pharmaceutical formulations in human cancer cell lines
Loredana Serpe et al.
JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY (2006)
Cholesteryl butyrate solid lipid nanoparticles inhibit adhesion of human neutrophils to endothelial cells
Chiara Dianzani et al.
BRITISH JOURNAL OF PHARMACOLOGY (2006)
Characterization of the effects of butyric acid on cell proliferation, cell cycle distribution and apoptosis
Tomoko Kurita-Ochiai et al.
FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY (2006)
SLC5A8 (SMCT1)-mediated transport of butyrate forms the basis for the tumor suppressive function of the transporter
N Gupta et al.
LIFE SCIENCES (2006)
Rationale for the Use of Histone Deacetylase Inhibitors as a Dual Therapeutic Modality in Multiple Sclerosis
Steven G. Gray et al.
EPIGENETICS (2006)
Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy
DC Drummond et al.
CANCER RESEARCH (2006)
Effects of topical treatment of sodium butyrate and 5-aminosalicylic acid on expression of trefoil factor 3, interleukin 1β, and nuclear factor κB in trinitrobenzene sulphonic acid induced colitis in rats
M Song et al.
POSTGRADUATE MEDICAL JOURNAL (2006)
Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma
U Heider et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2006)
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
S Minucci et al.
NATURE REVIEWS CANCER (2006)
Anticancer activities of histone deacetylase inhibitors
Jessica E. Bolden et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Butyric acid prodrugs are histone deacetylase inhibitors that show antineoplastic activity and radiosensitizing capacity in the treatment of malignant gliomas
M Entin-Meer et al.
MOLECULAR CANCER THERAPEUTICS (2005)
Oral butyrate for mildly to moderately active Crohn's disease
A Di Sabatino et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2005)
Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease
F Borovecki et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies
KN Bhalla
JOURNAL OF CLINICAL ONCOLOGY (2005)
Short-chain fatty acids modulate gene expression for vascular endothelial cell adhesion molecules
SJ Miller et al.
NUTRITION (2005)
Role of p53 status in chemosensitivity determination of cancer cells against histone deacetylase inhibitor sodium butyrate
J Joseph et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Shared epigenetic mechanisms in human and mouse gliomas inactivate expression of the growth suppressor SLC5A8
CB Hong et al.
CANCER RESEARCH (2005)
Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors
MJ Peart et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Butyrate suppresses Cox-2 activation in colon cancer cells through HDAC inhibition
X Tong et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
Modulation of angiogenesis-related protein synthesis by valproic acid
D Zgouras et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
Butyrate inhibits cytokine-induced VCAM-1 and ICAM-1 expression in cultured endothelial cells:: the role of NF-κB and PPARα
D Zapolska-Downar et al.
JOURNAL OF NUTRITIONAL BIOCHEMISTRY (2004)
Butyrate inhibits leukocyte adhesion to endothelial cells via modulation of VCAM-1
T Menzel et al.
INFLAMMATORY BOWEL DISEASES (2004)
Sodium butyrate and tributyrin induce in vivo growth inhibition and apoptosis in human prostate cancer
R Kuefer et al.
BRITISH JOURNAL OF CANCER (2004)
Sodium butyrate enhances Fas-mediated apoptosis of human hepatoma cells
K Ogawa et al.
JOURNAL OF HEPATOLOGY (2004)
Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer
T Reid et al.
LUNG CANCER (2004)
Expression profiling of sodium butyrate (NaB)-treated cells: identification of regulation of genes related to cytokine signaling and cancer metastasis by NaB
J Joseph et al.
ONCOGENE (2004)
Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells
S Nakata et al.
ONCOGENE (2004)
Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21waf1
V Chopin et al.
EXPERIMENTAL CELL RESEARCH (2004)
Restoration of transforming growth factor-β signaling through receptor RI induction by histone deacetylase activity inhibition in breast cancer cells
S Ammanamanchi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Cholesteryl butyrate solid lipid nanoparticles as a butyric acid pro-drug:: effects on cell proliferation, cell-cycle distribution and c-myc expression in human leukemic cells
L Serpe et al.
ANTI-CANCER DRUGS (2004)
Histone deacetylase inhibitor, FK228, induces apoptosis and suppresses cell proliferation of human glioblastoma cells in vitro and in vivo
H Sawa et al.
ACTA NEUROPATHOLOGICA (2004)
Sodium butyrate ameliorates phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy
M Minamiyama et al.
HUMAN MOLECULAR GENETICS (2004)
Aberrant methylation and histone deacetylation associated with silencing of SLC5A8 in gastric cancer
M Ueno et al.
TUMOR BIOLOGY (2004)
Cellular and physiological effects of short-chain fatty acids
SJ Miller
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2004)
Sodium butyrate sensitizes TRAIL-mediated apoptosis by induction of transcription from the DR5 gene promoter through Sp1 sites in colon cancer cells
YH Kim et al.
CARCINOGENESIS (2004)
Development of novel targeted therapies in the treatment of malignant glioma
JN Rich et al.
NATURE REVIEWS DRUG DISCOVERY (2004)
Histone deacetylase inhibitors
TA Miller et al.
JOURNAL OF MEDICINAL CHEMISTRY (2003)
Differential effects of short-chain fatty acids on proliferation and production of pro- and anti-inflammatory cytokines by cultured lymphocytes
CR Cavaglieri et al.
LIFE SCIENCES (2003)
Amelioration of dextran sulfate colitis by butyrate:: role of heat shock protein 70 and NF-κB
A Venkatraman et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2003)
Histone deacetylase inhibitors in cancer therapy: Is transcription the primary target?
RW Johnstone et al.
CANCER CELL (2003)
Duodenal administration of solid lipid nanoparticles loaded with different percentages of tobramycin
R Cavalli et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2003)
Topical butyrate improves efficacy of 5-ASA in refractory distal ulcerative colitis:: results of a multicentre trial
P Vernia et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2003)
New insight into butyrate metabolism
KEB Knudsen et al.
PROCEEDINGS OF THE NUTRITION SOCIETY (2003)
In vitro and in vivo study of solid lipid nanoparticles loaded with superparamagnetic iron oxide
E Peira et al.
JOURNAL OF DRUG TARGETING (2003)
Short-Chain Fatty Acid Inhibitors of Histone Deacetylases: Promising Anticancer Therapeutics?
James S. Chen et al.
CURRENT CANCER DRUG TARGETS (2003)
Intravenous administration to rabbits of non-stealth and stealth doxorubicin-loaded solid lipid nanoparticles at increasing concentrations of stealth agent:: Pharmacokinetics and distribution of doxorubicin in brain and other tissues
GP Zara et al.
JOURNAL OF DRUG TARGETING (2002)
Pharmacokinetics and tissue distribution of idarubicin-loaded solid lipid nanoparticles after duodenal administration to rats
GP Zara et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2002)
Butyrate strongly inhibits in vitro stimulated release of cytokines in blood
S Nancy et al.
DIGESTIVE DISEASES AND SCIENCES (2002)
Potentiating antitumor effects of a combination therapy with lovastatin and butyrate in the Lewis lung carcinoma model in mice
A Giermasz et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling
CF Deroanne et al.
ONCOGENE (2002)
Short-chain fatty acids inhibit invasive human colon cancer by modulating uPA, TIMP-1, TIMP-2, mutant p53, Bcl-2, Bax, p21 and PCNA protein expression in an in vitro cell culture model
NJ Emenaker et al.
JOURNAL OF NUTRITION (2001)
The effect of formulation and concentration of cholesteryl butyrate solid lipid nanospheres (SLN) on NIH-H460 cell proliferation
E Ugazio et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2001)
Treatment of spinal muscular atrophy by sodium butyrate
JG Chang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
The human histone deacetylase family
SG Gray et al.
EXPERIMENTAL CELL RESEARCH (2001)
In vitro effects of cholesteryl butyrate solid lipid nanospheres as a butyric acid pro-drug on melanoma cells: Evaluation of antiproliferative activity and apoptosis induction
B Salomone et al.
CLINICAL & EXPERIMENTAL METASTASIS (2001)
Prodrugs of butyric acid. Novel derivatives possessing increased aqueous solubility and potential for treating cancer and blood diseases
A Nudelman et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2001)
Cellular uptake and cytotoxicity of solid lipid nanospheres (SLN) incorporating doxorubicin or paclitaxel
A Miglietta et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2000)
Uptake of pivaloyloxymethyl butyrate into leukemic cells and its intracellular esterase-catalyzed hydrolysis
Y Zimra et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2000)
Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin:: Pharmacokinetics and tissue distribution after i.v. administration to rats
A Fundarò et al.
PHARMACOLOGICAL RESEARCH (2000)
Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation
VM Richon et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Histone deacetylase inhibitors: Inducers of differentiation or apoptosis of transformed cells
PA Marks et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Novel mutual prodrug of retinoic and butyric acids with enhanced anticancer activity
A Nudelman et al.
JOURNAL OF MEDICINAL CHEMISTRY (2000)
Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells
L Qiu et al.
MOLECULAR BIOLOGY OF THE CELL (2000)
Kill and cure: dietary augmentation of immune defences against colon cancer
F Armstrong et al.
PROCEEDINGS OF THE NUTRITION SOCIETY (2000)
P21-dependent G(1) arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228
V Sandor et al.
BRITISH JOURNAL OF CANCER (2000)
Biodistribution of stealth and non-stealth solid lipid nanospheres after intravenous administration to rats
V Podio et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2000)
Butyrate inhibits inflammatory responses through NF kappa B inhibition: implications for Crohn's disease
JP Segain et al.
GUT (2000)
Share Paper
